All News
RETRO - Taper or Not: You Decide
A prospective, phase 3 trial of rheumatoid arthritis (RA) patients in sustained remission has shown more than half will flare if disease-modifying antirheumatic drugs (DMARD) therapy is tapered or discontinued and that remission is best maintained by continued DMARD therapy.
Read Article
The heterogeneous 🌍🌎🌏 world prevalence of systemic #lupus reflects heterogeneity in:
➡️ Ethnic mix
➡️ Genetic background
➡️ Age & sex
➡️ Year of the study
➡️ Socio-economic factors
➡️ Epidemiological methods
➡️ Environmental factors (?)
Across populations https://t.co/QMJbJUf3vD
Laurent ARNAUD Lupusreference ( View Tweet)
Excited to share that the 2nd ed. Musculoskeletal Ultrasound in Rheumatology Review is the #1 new release in ultrasonography books on @amazon #ultrasound #RheumTwitter #meded #MedTwitter #POCUS #FOAMed https://t.co/b0ptm3MKid
Minna Kohler, MD, RhMSUS minnakohlermd ( View Tweet)
Upadacitinib was shown to be effective in two Phase 3 SELECT-AXIS trials. 1st trial: in bDMARD-IR AS pts the ASDAS resp was 44% vs 10% PBO at wk 14). 2nd trial: in nr-axSpA, the ASDAS response at wk 14: 42% vs 18% PBO. https://t.co/rnv9VVITeE
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib (oral TYK2 inhibitor) in development, has been shown to be highly effective in psoriasis & PsA, but failed to meet its primary endpoints at wk 12 (remission) in Ulcerative Colitis in the phase 2 LATTICE-UC trial vs placebo https://t.co/ZGYuozFgOk
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out the most recent podcast where we “Ask Cush Anything” and discuss a dozen news items from the last week.
https://t.co/Xb81eWEZ1q
#RheumNow
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full post on #RheumNow
https://t.co/tzPU1scc8x https://t.co/F537tPAQTU
Links:
Dr. John Cush RheumNow ( View Tweet)
WHO's Strategic Advisory Group on immunisation has advised an addition COVID vaccination in those >60 years and the immunosuppressed (due to a higher risk of breakthrough infections) https://t.co/NcGr8EMDaO
Links:
Dr. John Cush RheumNow ( View Tweet)
The CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million US adults have arthritis, 25.7 million of whom have AAAL.
Read more on #RheumNow
https://t.co/9RNIduVCZh https://t.co/fzxWMbcEfU
Links:
Dr. John Cush RheumNow ( View Tweet)
Most common reasons for starting canakinumab? Survey of 58 MDs (caring for 147 febrile pts) 1) perceived efficacy(81%), 2) lack of prior response (41%), 3) good safety (40%). Efficacy w/ HIDS/MKD (91%), no response w/ FMF (52%) https://t.co/JjxaUyBnyB
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/xxF1gIulwY
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Several studies have suggested that biologic Rx of Psoriasis may lower risk of later PsA. New study of nearly 2 million PSO (15k given biologic, 20K given oral Rx). The risk developing PsA higher w/ biologic (aHR 4.48) vs oral or phototherapy https://t.co/Na5EfWelkY https://t.co/0sL18UWjhO
Links:
Dr. John Cush RheumNow ( View Tweet)
We are reviewing cases from Ask Cush Anything and almost a dozen news items and reports on this week’s podcast. Download today.
https://t.co/Xb81eWEZ1q https://t.co/K6zPKtwAD7
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.
https://t.co/XOVKNj423l
#RheumNow https://t.co/CYxW6mJpCH
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs)
MTX = 0.8/100PY
ADA+MTX= 1.1/100PY
UPA 15 mg= 3.0/100PY
UPA 30 mg = 5.3/100PY
Hence there is a 4-5X risk of HZ w/ JAKinhibitors
https://t.co/wo9ih5PJ77
#RheumNow https://t.co/h1GoGzADdv
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/Cw6rSIUyW2
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function.
https://t.co/faLi0WQt8F https://t.co/PI7jYN1VB9
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7 https://t.co/qwbrvGkriX
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
ASBMR meeting presented results of the ASTEROID trial in osteogenesis imperfecta; Setrusumab, investigational Mab inhibitor of sclerostin, failed to improve radial trabecular BMD (primary endpt), but did improve lumbar/hip/femoral BMD https://t.co/xSDIiffjb7 https://t.co/H4Cl8rH3Bq
Links:
Dr. John Cush RheumNow ( View Tweet)
